



**ESPS PEER REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 11598

**Title:** Analysis of drug-resistant mutants induced by adefovir dipivoxil in patients with chronic HBV infection-related liver disease

**Reviewer code:** 00032933

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2014-05-28 21:07

**Date reviewed:** 2014-06-10 01:14

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

**COMMENTS TO AUTHORS**

1. In Study design and patients section, how many patients received ADV mutant study? This may show the incidence of ADV drug resistance mutant. 2. The duration of treatment when ADV resistant mutant appeared was not mention. This variable should be included in Table 2 (single mutant or multiple mutants) as well as Table 3 (rtA181T and non- rtA181T). 3. The discussion should be focus at the finding of this study. In general, the discussions were quite redundant. The first paragraph of discussion was not derived from data in this study that can be removed completely. 4. Studies have found that an rtA181T and rtN236T mutation /substitution could generate cross-resistance against tenofovir disoproxil fumarate (TDF). The cited references did not support this statement. 5. There is a higher prevalence of non-rtA181T in HBeAg positive patients (uni-variate analysis p=0.023). The mechanism and the significant of this finding were not discussed. If this finding remained significant in multi-variate analysis, a brief discussion will be needed. 6. The investigators suggested ADV monotherapy should not be used for patients with genotype C. Based on the data of this series, should we avoid ADV monotherapy to all patients when other drug with high resistance to mutant is available? 7. In the conclusion of the abstract, the author mentioned some of the mutant may be present before treatment. This sentence should be removed. No pre-treatment data in this study can be found.



**ESPS PEER REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 11598

**Title:** Analysis of drug-resistant mutants induced by adefovir dipivoxil in patients with chronic HBV infection-related liver disease

**Reviewer code:** 00012386

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2014-05-28 21:07

**Date reviewed:** 2014-06-19 13:09

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input checked="" type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

**COMMENTS TO AUTHORS**

Jiang et al. analyzed the mutation of HBV polymerase region in 79 ADV-resistant patients. Of interest, it seems an important study in this field. 1. In Introduction, page 2, lines 10-11, Does “....for HBV-related liver disease, as well as monotherapy subsequent to treatment with other NUCs for which the virus developed resistance” mean “for patients with HBV-related liver disease, as well as monotherapy to patients with NUCs-resistant HBV.”?? 2. In Introduction, page 2, last line, Do you mean “chronic HBV infection”? 3. In Methods section, How long study patients take ADV? How was doses? How the renal function? Authors should mention HBV genotype and HBeAg-status in the study population. How the methods for HBV genotype and HBeAg??